SAN DIEGO--(BUSINESS WIRE)--LATITUDE Pharmaceuticals, Inc. (LPI), a San Diego-based drug formulation developer, reported today that it is entering its fifth year of formulating a wide variety of poorly soluble/insoluble drug compounds using its proprietary intravenous (IV) nanoemulsion technology. To date, dozens of insoluble drug compounds have been formulated successfully with this approach and two (docetaxel and vinorelbine) are currently at the NDA-filing stage.
